Zoeken
target menu
... / ... / ... / ... / Newsfolder April 2012 / Symposium on Neurocognitive developmental...
 

Symposium on Neurocognitive developmental disorders

On May 25th, 2012 a scientific symposium is organized at Erasmus MC by the Expertise centre ENCORE with the topic of neurocognitive developmental disorders, such as NF1 and TSC.

Program of the symposium (download the program as a pdf file):

For registration and further information please contact: Mrs. Van Almenkerk: m.vanalmenkerk@erasmusmc.nl Neurodevelopmental disorders, mTOR and related pathways
Rotterdam, 25 May 2012
Place:  Erasmus MC – Sophia, Bioscoopzaal (Sp-3417) 3rd Floor
Dr. Molewaterplein 60, 3015 GJ Rotterdam

  • 12:30-12:35 Welcome by Chairman and Medical Director of Expertise Centre for Neurodevelopmental Disorders (ENCORE): Prof. Y. Elgersma
  • 12:35-13:05 Keynote lecture: Legius syndrome and MAPK pathway
    Prof. E. Legius, Department of Human Genetics, K.U. Leuven
  • 13:05-14:00  Lunch
  • 14:10-14:35  Diagnostics and monitoring of TSC based on imaging
    Dr. M.E.A.P.M. Adriaensen van Roij, Department of Radiology, Atrium MC Heerlen
  • 14:35- 15:00  Examining everolimus in TSC: the results of EXIST-1 and EXIST-2 trials
    Dr. B Zonnenberg, Department of Rare hereditary diseases. UMC Utrecht
  • 15:00-15:25 Neurocognitive profile of children with TSC as motivation for the RAPIT trial
    Drs. A.B. Rietman, Department of Child Neurology, Erasmus MC Rotterdam
  • 15:25- 15:45  Break
  • 15:45- 16:10  Benign and malignant tumors in NF1
    Prof. R.E. Ferner, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital London
  • 16:10-16:35  Pak inhibition as a novel strategy in TSC 
    Dr. M.M. Alves, Department of Gastroenterology & Hepathology, Erasmus MC Rotterdam
  • 16:25-16:50     Epilepsy in TSC; mechanism and treatment options
    Drs. I. Overwater, Department of Neuroscience, Erasmus MC Rotterdam
  • 16:50-17:00  Closure
    Dr. M.C.Y. de Wit, Department of Child Neurology, Erasmus MC Rotterdam,
  • 17:00- 17:30  Reception

This symposium is organized by ENCORE and Novartis Oncology

Date published: 9 May 2012